3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide has been researched along with amphetamine in 1 studies
| Studies (3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide) | Trials (3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide) | Recent Studies (post-2010) (3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide) | Studies (amphetamine) | Trials (amphetamine) | Recent Studies (post-2010) (amphetamine) |
|---|---|---|---|---|---|
| 14 | 0 | 6 | 13,071 | 329 | 1,977 |
| Protein | Taxonomy | 3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide (IC50) | amphetamine (IC50) |
|---|---|---|---|
| Phenylethanolamine N-methyltransferase | Bos taurus (cattle) | 0.96 | |
| Cytochrome P450 2A6 | Homo sapiens (human) | 3.5 | |
| Cytochrome P450 2A5 | Mus musculus (house mouse) | 2.85 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.96 | |
| Beta-2 adrenergic receptor | Cavia porcellus (domestic guinea pig) | 0.96 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beyaert, MG; Daya, RP; Dyck, BA; Johnson, RL; Mishra, RK | 1 |
1 other study(ies) available for 3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide and amphetamine
| Article | Year |
|---|---|
PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia.
Topics: Allosteric Regulation; Amphetamine; Animals; Behavior, Animal; Brain; Disease Models, Animal; Dopamine; Male; Motor Activity; Neostriatum; Nucleus Accumbens; Prefrontal Cortex; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Schizophrenia | 2013 |